Close to 120 companies across the globe claim to possess the required expertise and infrastructure ..

Development initiatives of HPAPIs and cytotoxic drugs are generally very demanding, both in terms of experience and capital investment. Most companies generally lack the necessary resources to meet the aforementioned requirements and are unable to set up dedicated HPAPI and cytotoxic drug manufacturing facilities. This has led to an increased demand for contract manufacturing service providers in this field.
 
To order this 300+ page report, which features 75+ figures and 150+ tables, please visit this link
 
The USD 25 billion (by 2030) financial opportunity within the HPAPI and cytotoxic drugs contract manufacturing market has been analyzed across the following segments:
Type of Product
HPAPIs
Highly Potent Finished Dosage Forms

  • Company Size
  • Small-sized
  • Mid-sized
  • Large / Very Large
Scale of Operation
  • Preclinical / Clinical
  • Commercial
Type of Pharmacological Molecule
  • Small Molecules
  • Biologics
Type of Highly Potent Finished Dosage Form
Injectables
Oral Solids
Creams
Others
Key geographical regions
North America
Europe
Asia Pacific
Rest of the World
The “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030report features the following companies, which we identified to be key players in this domain: 
  • AbbVie Contract Manufacturing
  • CARBOGEN AMCIS
  • Catalent
  • Evonik
  • Formosa Laboratories
  • Intas
  • Lonza
  • MabPlex
  • Pfizer CentreOne
 
Table of Contents
 
1. Preface

2. Executive Summary

3. Introduction


4. Market Landscape


5. Company Competitive Analysis


6. HPAPI and Cytotoxic Drugs Contract Manufacturers based in North America: Company Profiles


7. HPAPI and Cytotoxic Drugs Contract Manufacturers based in Europe: Company Profiles


8. HPAPI and Cytotoxic Drugs Contract Manufacturers based in Asia Pacific: Company Profiles


9. Partnerships and Collaborations


10. Recent Expansions


11. Capacity Analysis


12. Market Sizing and Opportunity Analysis


13. Case-In-Point: Contract Manufacturing of Antibody Drug Conjugates
14. Concluding Remarks
15. Executive Insights
16. Appendix 1: Tabulated Data
17. Appendix 2: List of Companies and Organizations
 
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html  
 
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]  

You may also like

Discussion

No comments yet... Be the first to leave a reply! Login here

avatar
BenJ
0 Karma
880 Posts

Made with by Mamby